Biotechnology/Chemical/Pharmaceutical Customer Partnership

Wednesday, June 6, 2012
9:00am to 4:30pm

United States Patent and Trademark Office
Alexandria, Virginia
Madison Auditorium
600 Dulany Street, Alexandria, VA

The most recent quarterly meeting for the Biotechnology and Chemical Pharmaceutical Customer Partnership was held on March 6, 2012 at the U.S. Patent and Trademark Office. The Biotechnology and Chemical Pharmaceutical Customer Partnership is designed and developed to be a forum to share ideas, experiences, and insights between individual users and the USPTO. The USPTO does not intend to use these customer partnership groups to arrive at any consensus. Invitations to participate will indicate that individual opinions are sought, rather than a group consensus and that the meetings are intended to be informal in nature and have varying participants. These customer partnership groups are formed with full recognition of the USPTO's responsibility under the Federal Advisory Committee Act (FACA), and that these customer partnership groups are not established as FACA compliant committees.
We value our customers in obtaining feedback from individual participants is important in our efforts to continuously improve the quality of our products and services. Your willing participation is helpful in providing us with insights and experiences in this informal process to assist us.

The next meeting of the U.S. Patent and Trademark Office Biotechnology and Chemical Pharmaceutical Customer Partnership is scheduled for Wednesday, June 6, 2012 from 9:00 am to 4:30 PM at Auditorium in Madison East, 600 Dulany Street, Alexandria, Virginia.

For information of future meetings and presentations, please go to

Please contact Cecilia Tsang at 571-272-0562, or by fax at 571-273-0562, or email to decline or confirm your attendance by June 4, 2012.



Agenda and Schedule for the Biotechnology and Chemical Pharmaceutical Customer Partnership Meeting

Morning Session
9:00 - 9:15Opening RemarksGeorge Elliott, Wanda Walker and Peter Paras (Acting), Directors, TC1600
9:15 - 10:15AIA UpdateJanet Gongola, Patent Reform Coordinator

10:15 -10:30

10:30 - 11:00Cooperative Patent Classification OverviewJerry Lorengo, SPE, TC1700
11:00 - 12:00Claim InterpretationJeffrey Lundgren, SPE, Art Unit 1629
12:00 - 1:15 Lunch
Afternoon Session
1:15 - 2:45Mayo v. PrometheusRoberte Makowski, Connolly Bove Lodge & Hutz, LLP, Hans Sauer, Associate General Counsel for BIO
2:45 - 3:00Break 
3:00 - 3:30Recommendation for the Disclosure of Sequence Listings using XML (Proposed ST.26)Susan Wolski, PCT Legal
3:30 - 4:15Range Limitations in ClaimsJean Witz, QAS, TC1600
4:15 - 4:30Closing Remarks/DiscussionGeorge Elliott, Wanda Walker and Peter Paras (Acting), Directors, TC1600


Proposed ST.26

The meeting agenda has been updated by the addition of the talk Recommendation for the Disclosure of Sequence Listings using XML (Proposed ST.26). A Federal Register Notice requesting comments on the recommendation for the disclosure of sequence listings Using XML (Proposed ST.26) is published and is available at this link or by cut and paste of the url ( into a browser.

Accessing the event online via WebEx

To join the online event


1. Go to

2. Click "Join Now".


To join the teleconference only


Call-in toll number (US/Canada): +1-408-600-3600

Access code: 991 681 937


For assistance


You can contact USPTO WebEx at:

The playback of UCF (Universal Communications Format) rich media files requires appropriate players. To view this type of rich media files in the meeting, please check whether you have the players installed on your computer by going to

IMPORTANT NOTICE: This WebEx service includes a feature that allows audio and any documents and other materials exchanged or viewed during the session to be recorded. By joining this session, you automatically consent to such recordings. If you do not consent to the recording, discuss your concerns with the meeting host prior to the start of the recording or do not join the session. Please note that any such recordings may be subject to discovery in the event of litigation.